Aldeyra Therapeutics Inc.

3.15+0.0300+0.96%Vol 813.09K1Y Perf -49.68%
Dec 6th, 2023 16:00 DELAYED
BID3.12 ASK3.25
Open3.21 Previous Close3.12
Pre-Market- After-Market3.24
 - -  0.09 2.86%
Target Price
17.00 
Analyst Rating
Strong Buy 1.50
Potential %
439.68 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.40 
Earnings Rating
Strong Buy
Market Cap185.29M 
Earnings Date
7th Dec 2023
Alpha0.00 Standard Deviation0.26
Beta1.40 

Today's Price Range

3.053.25

52W Range

1.4211.97

5 Year PE Ratio Range

-4.50-3.90

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
13.72%
1 Month
13.72%
3 Months
-56.37%
6 Months
-72.56%
1 Year
-49.68%
3 Years
-55.63%
5 Years
-65.87%
10 Years
-

TickerPriceChg.Chg.%
ALDX3.150.03000.96
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
7.70
7.80
0.02
0.10
-38.40
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.31-0.1551.61
Q01 2023-0.30-0.2710.00
Q04 2022-0.34-0.2235.29
Q03 2022-0.34-0.2526.47
Q02 2022-0.32-0.306.25
Q01 2022-0.31-0.296.45
Q04 2021-0.31-0.2712.90
Q03 2021-0.29-0.276.90
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.2414.29Positive
12/2023 QR-0.2037.50Positive
12/2023 FY-0.7629.63Positive
12/2024 FY-1.0812.90Positive
Next Report Date7th Dec 2023
Estimated EPS Next Report-0.24
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume813.09K
Shares Outstanding58.82K
Shares Float54.53M
Trades Count7.31K
Dollar Volume2.57M
Avg. Volume1.84M
Avg. Weekly Volume1.43M
Avg. Monthly Volume1.47M
Avg. Quarterly Volume2.64M

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) stock closed at 3.15 per share at the end of the most recent trading day (a 0.96% change compared to the prior day closing price) with a volume of 813.09K shares and market capitalization of 185.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aldeyra Therapeutics Inc. CEO is Todd C. Brady.

The one-year performance of Aldeyra Therapeutics Inc. stock is -49.68%, while year-to-date (YTD) performance is -54.74%. ALDX stock has a five-year performance of -65.87%. Its 52-week range is between 1.42 and 11.97, which gives ALDX stock a 52-week price range ratio of 16.40%

Aldeyra Therapeutics Inc. currently has a PE ratio of -6.30, a price-to-book (PB) ratio of 2.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -32.51%, a ROC of -31.13% and a ROE of -37.26%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aldeyra Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Aldeyra Therapeutics Inc.’s next earnings report date is 07th Dec 2023.

The consensus rating of Wall Street analysts for Aldeyra Therapeutics Inc. is Strong Buy (1.5), with a target price of $17, which is +439.68% compared to the current price. The earnings rating for Aldeyra Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aldeyra Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aldeyra Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.48, ATR14 : 0.30, CCI20 : 202.37, Chaikin Money Flow : -0.03, MACD : -0.03, Money Flow Index : 76.60, ROC : 25.30, RSI : 56.01, STOCH (14,3) : 73.80, STOCH RSI : 0.72, UO : 56.39, Williams %R : -26.20), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aldeyra Therapeutics Inc. in the last 12-months were: Brady Todd (Option Excercise at a value of $150 182), Bronstein Ben (Option Excercise at a value of $5 282), Phillips Gary (Option Excercise at a value of $2 990), Walker Neal (Option Excercise at a value of $5 282)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.00

Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

CEO: Todd C. Brady

Telephone: +1 781 761-4904

Address: 131 Hartwell Avenue, Lexington 02421, MA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

61%39%

Bearish Bullish

59%41%

 

News

Stocktwits